Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Lymphoma
Lymphoma, Follicular


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2022 Oct 2030

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Intervention Arm Group : Axicabtagene Ciloleucel;

Intervention Type : DRUG
Intervention Description : Administered intravenously

Intervention Arm Group : Axicabtagene Ciloleucel;Standard of Care Therapy;

Intervention Type : DRUG
Intervention Description : Administered intravenously

Intervention Arm Group : Axicabtagene Ciloleucel;

Intervention Type : DRUG
Intervention Description : Administered orally

Intervention Arm Group : Standard of Care Therapy;

Intervention Type : DRUG
Intervention Description : Administered intravenously

Intervention Arm Group : Standard of Care Therapy;

Intervention Type : DRUG
Intervention Description : Administered intravenously

Intervention Arm Group : Standard of Care Therapy;

Intervention Type : DRUG
Intervention Description : Administered intravenously

Intervention Arm Group : Standard of Care Therapy;

Intervention Type : DRUG
Intervention Description : Administered orally

Intervention Arm Group : Standard of Care Therapy;

Intervention Type : DRUG
Intervention Description : Administered intravenously

Intervention Arm Group : Standard of Care Therapy;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • King's College Hospital NHS Foundation Trust
    London
    SE5 9RS
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge
    CB2 2QQ
  • The Royal Marsden NHS Foundation Trust
    Sutton
    SM2 5PT
  • Oxford University Hospitals NHS Foundation Trust
    Oxford
    OX3 7LE
  • University Hospital Birmingham NHS Foundation Trust
    Birmingham
    B15 2GW
  • The University Hospital Southampton NHS Foundation Trust
    Southampton
    SO16 6YD
  • University College London Hospitals NHS Foundation Trust
    London
    NW2 2QG
  • The Christie NHS Foundation Trust
    Manchester
    M20 4BX


The study is sponsored by Kite, A Gilead Company




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05371093
Last updated 07 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.